title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Stocks That Hit 52-Week Lows On Friday,20220506T160650,https://www.benzinga.com/markets/options/22/05/27050916/52-weeks-high-and-low-article,LVTX,0.005467,Neutral,0.001296
Stocks That Hit 52-Week Lows On Wednesday,20220427T184104,https://www.benzinga.com/markets/options/22/04/26844275/52-weeks-high-and-low-article,LVTX,0.006956,Neutral,0.00022
"Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results - Intelligent Bio Solutions  ( NASDAQ:INBS ) , Akoustis Technologies  ( NASDAQ:AKTS ) ",20240125T180822,https://www.benzinga.com/news/earnings/24/01/36786638/crude-oil-rises-2-tesla-shares-plunge-after-downbeat-results,LVTX,0.119235,Somewhat-Bullish,0.249736
"Dow Surges Over 100 Points; US GDP Growth Tops Estimates - Intelligent Bio Solutions  ( NASDAQ:INBS ) , Akoustis Technologies  ( NASDAQ:AKTS ) ",20240125T154228,https://www.benzinga.com/news/earnings/24/01/36783052/dow-surges-over-100-points-us-gdp-growth-tops-estimates,LVTX,0.156461,Somewhat-Bullish,0.250309
"VistaGen Therapeutics, Inc.  ( VTGN )  Reports Q2 Loss, Misses Revenue Estimates",20221110T234509,https://www.zacks.com/stock/news/2017060/vistagen-therapeutics-inc-vtgn-reports-q2-loss-misses-revenue-estimates,LVTX,0.208764,Neutral,0.0
Stocks That Hit 52-Week Lows On Friday,20220610T154524,https://www.benzinga.com/markets/options/22/06/27650434/52-weeks-high-and-low-article,LVTX,0.013393,Somewhat-Bearish,-0.227363
"CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors - Cargo Therapeutics  ( NASDAQ:CRGX ) ",20240415T200500,https://www.benzinga.com/pressreleases/24/04/g38258186/cargo-therapeutics-names-kapil-dhingra-m-b-b-s-to-board-of-directors,LVTX,0.033846,Neutral,0.0
Stocks That Hit 52-Week Lows On Friday,20220429T164424,https://www.benzinga.com/markets/options/22/04/26902449/52-weeks-high-and-low-article,LVTX,0.02594,Neutral,0.001035
"Reunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical Affairs",20221024T113000,https://www.globenewswire.com/news-release/2022/10/24/2539849/0/en/Reunion-Neuroscience-Appoints-Chief-Financial-Officer-and-Vice-President-Medical-Affairs.html,LVTX,0.036812,Neutral,0.02085
"Reunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical Affairs - Reunion Neuroscience  ( NASDAQ:REUN ) ",20221024T113000,https://www.benzinga.com/pressreleases/22/10/g29376187/reunion-neuroscience-appoints-chief-financial-officer-and-vice-president-medical-affairs,LVTX,0.035086,Neutral,0.020685
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors,20230309T130500,https://www.globenewswire.com/news-release/2023/03/09/2624088/0/en/LAVA-Therapeutics-Announces-Appointment-of-Christy-J-Oliger-to-its-Board-of-Directors.html,LVTX,0.295867,Neutral,0.011025
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors - LAVA Therapeutics  ( NASDAQ:LVTX ) ,20230309T130500,https://www.benzinga.com/pressreleases/23/03/g31275266/lava-therapeutics-announces-appointment-of-christy-j-oliger-to-its-board-of-directors,LVTX,0.216215,Neutral,0.119314
"Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket - Amesite  ( NASDAQ:AMST ) , BIMI Intl Medical  ( NASDAQ:BIMI ) ",20221214T113012,https://www.benzinga.com/news/22/12/30072498/why-vallon-pharmaceuticals-shares-are-trading-higher-by-over-150-here-are-29-stocks-moving-premarket,LVTX,0.151222,Neutral,-0.112155
"Evogene  ( EVGN )  Reports Q2 Loss, Lags Revenue Estimates",20230817T121511,https://www.zacks.com/stock/news/2137362/evogene-evgn-reports-q2-loss-lags-revenue-estimates,LVTX,0.211191,Neutral,0.0
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027,20241210T123000,https://www.globenewswire.com/news-release/2024/12/10/2994415/0/en/LAVA-Reports-Third-Quarter-2024-Financial-Results-and-Announces-Pipeline-Reprioritization-and-Cash-Runway-Extension-into-2027.html,LVTX,0.09638,Neutral,0.061595
LAVA Reports Second Quarter 2024 Financial Results and Business Update,20240820T113000,https://www.globenewswire.com/news-release/2024/08/20/2932711/0/en/LAVA-Reports-Second-Quarter-2024-Financial-Results-and-Business-Update.html,LVTX,0.050201,Neutral,-0.018
All You Need to Know About LAVA Therapeutics  ( LVTX )  Rating Upgrade to Strong Buy,20240722T160011,https://www.zacks.com/stock/news/2306261/all-you-need-to-know-about-lava-therapeutics-lvtx-rating-upgrade-to-strong-buy,LVTX,0.362505,Bullish,0.389331
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference,20240620T113000,https://www.globenewswire.com/news-release/2024/06/20/2901588/0/en/LAVA-Therapeutics-to-Participate-in-the-H-C-Wainwright-2nd-Annual-Immune-Cell-Engager-Virtual-Conference.html,LVTX,0.560594,Neutral,0.041268
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference - LAVA Therapeutics  ( NASDAQ:LVTX ) ,20240620T113000,https://www.benzinga.com/pressreleases/24/06/g39408416/lava-therapeutics-to-participate-in-the-h-c-wainwright-2nd-annual-immune-cell-engager-virtual-conf,LVTX,0.552443,Neutral,0.037412
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results,20240521T110000,https://www.globenewswire.com/news-release/2024/05/21/2885427/0/en/LAVA-Provides-Business-Updates-and-Reports-First-Quarter-2024-Financial-Results.html,LVTX,0.056741,Neutral,-0.019035
Doctor's Orders - biotech stocks to watch  ( NASDAQ: LVTX )   ( NASDAQ: NKGN )   ( Nasdaq: KNSA )   ( Nasdaq: GOSS ) ,20240320T133646,https://www.investorideas.com/news/2024/main/03201Stocks.asp,LVTX,0.089462,Neutral,-0.072485
"Eton Pharmaceuticals, Inc.  ( ETON )  Reports Q4 Loss, Lags Revenue Estimates",20240314T211506,https://www.zacks.com/stock/news/2241002/eton-pharmaceuticals-inc-eton-reports-q4-loss-lags-revenue-estimates,LVTX,0.205225,Neutral,0.0
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052  ( formerly SGN-EGFRd2/LAVA-1223 ) ,20240305T123000,https://www.globenewswire.com/news-release/2024/03/05/2840325/0/en/LAVA-Announces-Clinical-Development-Milestone-Achieved-by-Pfizer-for-PF-08046052-formerly-SGN-EGFRd2-LAVA-1223.html,LVTX,0.100308,Neutral,0.007691
"'s 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet  ( Donald Trump Has Re-Entered The Chat )  - American Superconductor  ( NASDAQ:AMSC ) , American Airlines Group  ( NASDAQ:AAL ) ",20240126T165016,https://www.benzinga.com/general/biotech/24/01/36804956/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-donald-,LVTX,0.102668,Neutral,0.018708
Why Is LAVA Therapeutics Nano Cap Stock Trading Higher Today? - LAVA Therapeutics  ( NASDAQ:LVTX ) ,20240125T151121,https://www.benzinga.com/general/biotech/24/01/36782380/why-is-cancer-focused-lava-therapeutics-nano-cap-stock-trading-higher-today,LVTX,0.47379,Neutral,0.052779
"LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDAÂ®",20240125T120000,https://www.globenewswire.com/news-release/2024/01/25/2816550/0/en/LAVA-Therapeutics-Announces-Collaboration-with-Merck-Co-Inc-Rahway-NJ-USA-to-Evaluate-LAVA-1207-in-Combination-with-KEYTRUDA.html,LVTX,0.110802,Neutral,-0.047639
"Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Key Companies - Bristol Myers Squibb, Innate Pharma, Kymera Therapeutics, EUSA Pharma, Abcuro, Dren Bio, Novotech",20231016T210100,https://www.prnewswire.com/news-releases/large-granular-lymphocyte-leukemia-market-is-projected-to-grow-during-the-study-period-20192032-assesses-delveinsight--key-companies---bristol-myers-squibb-innate-pharma-kymera-therapeutics-eusa-pharma-abcuro-dren-bio-n-301957023.html,LVTX,0.025845,Neutral,-0.026539
"Acute Lymphocytic Leukemia Market to Accelerate Substantially by 2032, Assesses DelveInsight | Key Companies in the Market - Beam, Pfizer, Genentech, AbbVie, Fate, Roche, Ascentage, Janssen, Jazz, ADC, Kymera, Syndax, ImmunoGen",20230913T210100,https://www.prnewswire.com/news-releases/acute-lymphocytic-leukemia-market-to-accelerate-substantially-by-2032-assesses-delveinsight--key-companies-in-the-market---beam-pfizer-genentech-abbvie-fate-roche-ascentage-janssen-jazz-adc-kymera-syndax-immunogen-301925772.html,LVTX,0.021897,Neutral,0.047845
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference,20230906T111100,https://www.globenewswire.com/news-release/2023/09/06/2738237/0/en/LAVA-Therapeutics-to-Participate-in-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html,LVTX,0.443626,Neutral,0.02093
"LAVA Therapeutics N.V.  ( LVTX )  Reports Q2 Loss, Tops Revenue Estimates",20230822T121503,https://www.zacks.com/stock/news/2138986/lava-therapeutics-nv-lvtx-reports-q2-loss-tops-revenue-estimates,LVTX,0.40348,Neutral,0.100939
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results,20230822T110000,https://www.globenewswire.com/news-release/2023/08/22/2729337/0/en/LAVA-Therapeutics-Provides-Business-Update-and-Reports-Second-Quarter-2023-Financial-Results.html,LVTX,0.025192,Neutral,0.010482
"Aravive  ( ARAV )  Reports Q2 Loss, Tops Revenue Estimates",20230821T215004,https://www.zacks.com/stock/news/2138885/aravive-arav-reports-q2-loss-tops-revenue-estimates,LVTX,0.211191,Neutral,0.0
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference - LAVA Therapeutics  ( NASDAQ:LVTX ) ,20230814T110026,https://www.benzinga.com/pressreleases/23/08/g33825889/lava-therapeutics-to-participate-in-the-h-c-wainwright-immune-cell-engager-virtual-conference,LVTX,0.504646,Neutral,0.070504
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference,20230814T110000,https://www.globenewswire.com/news-release/2023/08/14/2724253/0/en/LAVA-Therapeutics-to-Participate-in-the-H-C-Wainwright-Immune-Cell-Engager-Virtual-Conference.html,LVTX,0.462395,Neutral,0.049279
GMAB: Invest in These 3 High-Growth Biotech Stocks,20230710T155053,https://stocknews.com/news/gmab-incy-lvtx-invest-in-these-3-high-growth-biotech-stocks/,LVTX,0.157483,Somewhat-Bullish,0.180677
"Lava  ( LVTX )  Discontinues Hematological Tumor Study, Shares Fall",20230615T134300,https://www.zacks.com/stock/news/2108856/lava-lvtx-discontinues-hematological-tumor-study-shares-fall,LVTX,0.29234,Somewhat-Bearish,-0.244997
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway,20230614T130000,https://www.globenewswire.com/news-release/2023/06/14/2688107/0/en/LAVA-Therapeutics-Provides-Updates-on-Clinical-Programs-and-Extends-the-Cash-Runway.html,LVTX,0.035555,Neutral,0.010857
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results,20230608T110000,https://www.globenewswire.com/news-release/2023/06/08/2684602/0/en/LAVA-Therapeutics-Provides-Business-Update-and-Reports-First-Quarter-2023-Financial-Results.html,LVTX,0.055621,Neutral,0.073054
LAVA  ( LVTX )  Up on J&J's  ( JNJ )  Cancer Study Candidate Selection,20230602T145900,https://www.zacks.com/stock/news/2103223/lava-lvtx-up-on-jjs-jnj-cancer-study-candidate-selection,LVTX,0.634626,Somewhat-Bullish,0.233642
"Why Lululemon Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Broadcom  ( NASDAQ:AVGO ) , Ascent Solar Technologies  ( NASDAQ:ASTI ) ",20230602T115818,https://www.benzinga.com/news/23/06/32688337/why-lululemon-shares-are-trading-higher-by-15-here-are-20-stocks-moving-premarket,LVTX,0.196877,Somewhat-Bullish,0.315234
LAVA Announces Annual Meeting of Shareholders,20230530T212800,https://www.globenewswire.com/news-release/2023/05/30/2678898/0/en/LAVA-Announces-Annual-Meeting-of-Shareholders.html,LVTX,0.380978,Neutral,-0.005389
Is a Beat Likely for Cooper Companies  ( COO )  in Q2 Earnings?,20230530T120300,https://www.zacks.com/stock/news/2101281/is-a-beat-likely-for-cooper-companies-coo-in-q2-earnings,LVTX,0.257668,Somewhat-Bullish,0.221955
MNKD: 3 Biotech Stocks Primed for Growth,20230516T162509,https://stocknews.com/news/mnkd-pnt-lvtx-3-biotech-stocks-primed-for-growth/,LVTX,0.235537,Somewhat-Bullish,0.275013
"Fortress Biotech  ( FBIO )  Reports Q1 Loss, Lags Revenue Estimates",20230515T211509,https://www.zacks.com/stock/news/2095478/fortress-biotech-fbio-reports-q1-loss-lags-revenue-estimates,LVTX,0.20698,Neutral,0.0
"Geron  ( GERN )  Reports Q1 Loss, Misses Revenue Estimates",20230511T131507,https://www.zacks.com/stock/news/2094114/geron-gern-reports-q1-loss-misses-revenue-estimates,LVTX,0.210579,Neutral,0.0
"Selecta Biosciences, Inc.  ( SELB )  Reports Q1 Loss, Misses Revenue Estimates",20230504T124515,https://www.zacks.com/stock/news/2089870/selecta-biosciences-inc-selb-reports-q1-loss-misses-revenue-estimates,LVTX,0.204647,Neutral,0.0
LVTX: 1 Biotech Stock to Buy in April 2023 and 1 to Sell,20230404T192303,https://stocknews.com/news/lvtx-tals-1-biotech-stock-to-buy-in-april-2023-and-1/,LVTX,0.374714,Somewhat-Bullish,0.171603
"ITeos Therapeutics, Inc.  ( ITOS )  Q4 Earnings and Revenues Surpass Estimates",20230315T123503,https://www.zacks.com/stock/news/2065955/iteos-therapeutics-inc-itos-q4-earnings-and-revenues-surpass-estimates,LVTX,0.204647,Neutral,0.0
"Curis  ( CRIS )  Reports Q4 Loss, Misses Revenue Estimates",20230313T131505,https://www.zacks.com/stock/news/2064667/curis-cris-reports-q4-loss-misses-revenue-estimates,LVTX,0.211191,Neutral,0.0
LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference - LAVA Therapeutics  ( NASDAQ:LVTX ) ,20230209T120000,https://www.benzinga.com/pressreleases/23/02/g30830131/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference,LVTX,0.509589,Neutral,0.012916
LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer,20230206T120000,https://www.globenewswire.com/news-release/2023/02/06/2601922/0/en/LAVA-Therapeutics-Announces-the-Appointment-of-Dr-Charles-Morris-as-Chief-Medical-Officer.html,LVTX,0.175859,Neutral,0.011877
LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer - LAVA Therapeutics  ( NASDAQ:LVTX ) ,20230206T120000,https://www.benzinga.com/pressreleases/23/02/g30725682/lava-therapeutics-announces-the-appointment-of-dr-charles-morris-as-chief-medical-officer,LVTX,0.172097,Neutral,0.01021
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium,20230123T120000,https://www.globenewswire.com/news-release/2023/01/23/2593053/0/en/LAVA-Therapeutics-to-Present-LAVA-1207-Clinical-Data-at-the-2023-ASCO-GU-Symposium.html,LVTX,0.059194,Neutral,-0.068127
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium,20230123T120000,https://www.benzinga.com/pressreleases/23/01/g30519487/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium,LVTX,0.112797,Neutral,-0.073443
LAVA Therapeutics Announces Appointment of New Directors to the Board - LAVA Therapeutics  ( NASDAQ:LVTX ) ,20230106T180754,https://www.benzinga.com/pressreleases/23/01/g30314713/lava-therapeutics-announces-appointment-of-new-directors-to-the-board,LVTX,0.159922,Neutral,0.14612
LAVA Therapeutics Announces Appointment of New Directors to the Board,20230106T180700,https://www.globenewswire.com/news-release/2023/01/06/2584625/0/en/LAVA-Therapeutics-Announces-Appointment-of-New-Directors-to-the-Board.html,LVTX,0.217834,Neutral,0.055309
LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference,20230103T120000,https://www.globenewswire.com/news-release/2023/01/03/2581976/0/en/LAVA-Therapeutics-to-Present-at-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html,LVTX,0.570165,Somewhat-Bearish,-0.157222
LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference - LAVA Therapeutics  ( NASDAQ:LVTX ) ,20230103T120000,https://www.benzinga.com/pressreleases/23/01/g30254188/lava-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference,LVTX,0.388879,Neutral,-0.045536
LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology  ( ASH )  Annual Meeting and Exposition,20221210T150000,https://www.globenewswire.com/news-release/2022/12/10/2571386/0/en/LAVA-Therapeutics-Announces-Updated-Data-from-the-Phase-1-2a-Clinical-Trial-of-LAVA-051-at-the-64th-American-Society-of-Hematology-ASH-Annual-Meeting-and-Exposition.html,LVTX,0.169915,Neutral,-0.00145
Can LAVA Therapeutics N.V.  ( LVTX )  Climb 198% to Reach the Level Wall Street Analysts Expect?,20221125T145505,https://www.zacks.com/stock/news/2022380/can-lava-therapeutics-nv-lvtx-climb-198-to-reach-the-level-wall-street-analysts-expect,LVTX,0.2842,Bullish,0.366274
LAVA Therapeutics N.V.  ( LVTX )  Q3 Earnings Surpass Estimates,20221116T222505,https://www.zacks.com/stock/news/2019094/lava-therapeutics-nv-lvtx-q3-earnings-surpass-estimates,LVTX,0.397098,Neutral,0.093323
Will LAVA Therapeutics N.V.  ( LVTX )  Report Negative Q3 Earnings? What You Should Know,20221114T150008,https://www.zacks.com/stock/news/2017927/will-lava-therapeutics-nv-lvtx-report-negative-q3-earnings-what-you-should-know,LVTX,0.296463,Neutral,0.004451
"Viridian Therapeutics, Inc.  ( VRDN )  Reports Q3 Loss, Tops Revenue Estimates",20221114T131505,https://www.zacks.com/stock/news/2017705/viridian-therapeutics-inc-vrdn-reports-q3-loss-tops-revenue-estimates,LVTX,0.205225,Neutral,0.0
"Cytek Biosciences, Inc.  ( CTKB )  Q3 Earnings Surpass Estimates",20221109T224513,https://www.zacks.com/stock/news/2016386/cytek-biosciences-inc-ctkb-q3-earnings-surpass-estimates,LVTX,0.2035,Neutral,0.0
LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer,20221101T110000,https://www.globenewswire.com/news-release/2022/11/01/2545292/0/en/LAVA-Therapeutics-Announces-Appointment-of-Fred-M-Powell-as-Chief-Financial-Officer.html,LVTX,0.288044,Neutral,0.073502
Seagen Inc.  ( SGEN )  Q3 2022 Earnings Call Transcript,20221028T063039,https://www.fool.com/earnings/call-transcripts/2022/10/28/seagen-inc-sgen-q3-2022-earnings-call-transcript/,LVTX,0.005164,Neutral,0.037301
"Insmed  ( INSM )  Reports Q3 Loss, Misses Revenue Estimates",20221027T124513,https://www.zacks.com/stock/news/1998331/insmed-insm-reports-q3-loss-misses-revenue-estimates,LVTX,0.205225,Neutral,0.0
Analyst Says This Small Cap Stock Might Be 'Game Changer' In Bispecific T Cell Engagers Space - LAVA Therapeutics  ( NASDAQ:LVTX ) ,20221025T182626,https://www.benzinga.com/analyst-ratings/analyst-color/22/10/29403318/analyst-says-this-small-cap-stock-might-be-game-changer-in-bispecific-t-cell-engage,LVTX,0.605266,Neutral,0.079372
LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer  ( SITC )  2022 Annual Meeting - LAVA Therapeutics  ( NASDAQ:LVTX ) ,20221007T150000,https://www.benzinga.com/pressreleases/22/10/g29185945/lava-therapeutics-to-present-on-mechanism-pharmacodynamics-data-from-the-phase-12a-clinical-trial-,LVTX,0.192694,Neutral,0.0561
LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer  ( SITC )  2022 Annual Meeting,20221007T150000,https://www.globenewswire.com/news-release/2022/10/07/2530377/0/en/LAVA-Therapeutics-to-Present-On-Mechanism-Pharmacodynamics-Data-from-the-Phase-1-2a-Clinical-Trial-of-LAVA-051-at-the-Society-for-Immunotherapy-of-Cancer-SITC-2022-Annual-Meeting.html,LVTX,0.138066,Neutral,-0.069367
Will Seagen's  ( SGEN )  Portfolio of Drugs Help Combat Rivalry?,20221004T140500,https://www.zacks.com/stock/news/1987853/will-seagens-sgen-portfolio-of-drugs-help-combat-rivalry,LVTX,0.172713,Somewhat-Bullish,0.325055
Seagen  ( SGEN )  Inks Deal With LAVA Therapeutics for LAVA-1223,20220927T154400,https://www.zacks.com/stock/news/1985550/seagen-sgen-inks-deal-with-lava-therapeutics-for-lava-1223,LVTX,0.220141,Bullish,0.371012
"Snap To Surge Around 20%? Here Are 5 Other Price Target Changes For Tuesday - Keurig Dr Pepper  ( NASDAQ:KDP ) , Domino's Pizza  ( NYSE:DPZ ) ",20220927T110919,https://www.benzinga.com/news/22/09/29026640/snap-to-surge-around-20-here-are-5-other-price-target-changes-for-tuesday,LVTX,0.465196,Bullish,0.564729
"Nasdaq Turns Lower; Crude Oil Drops Sharply - Golden Sun Education Gr  ( NASDAQ:GSUN ) , Aditxt  ( NASDAQ:ADTX ) ",20220926T184935,https://www.benzinga.com/news/earnings/22/09/29018181/nasdaq-turns-lower-crude-oil-drops-sharply,LVTX,0.158519,Somewhat-Bullish,0.334008
Hot Penny Stocks To Watch As The Stock Market Crash Continues,20220926T183016,https://pennystocks.com/featured/2022/09/26/hot-penny-stocks-to-watch-as-the-stock-market-crash-continues/,LVTX,0.151301,Neutral,0.127971
"Stocks making the biggest moves midday: Wynn Resorts, Planet Fitness, AMC, Lyft and more",20220926T164736,https://www.cnbc.com/2022/09/26/stocks-making-the-biggest-moves-midday-wynn-resorts-planet-fitness-amc-lyft-and-more.html,LVTX,0.067536,Neutral,0.080183
"Dow Drops Over 100 Points; Crude Oil Rises Over 1% - Golden Sun Education Gr  ( NASDAQ:GSUN ) , Inpixon  ( NASDAQ:INPX ) ",20220926T161059,https://www.benzinga.com/news/earnings/22/09/29014630/dow-drops-over-100-points-crude-oil-rises-over-1,LVTX,0.152983,Somewhat-Bullish,0.327202
"US Stocks Mostly Higher; Nasdaq Rises Over 100 Points - Aditxt  ( NASDAQ:ADTX ) , Avenue Therapeutics  ( NASDAQ:ATXI ) ",20220926T142818,https://www.benzinga.com/news/22/09/29010889/us-stocks-mostly-higher-nasdaq-rises-over-100-points,LVTX,0.136888,Somewhat-Bullish,0.308291
Why LAVA Therapeutics Stock Is Up More Than 100% Today - LAVA Therapeutics  ( NASDAQ:LVTX ) ,20220926T132755,https://www.benzinga.com/news/22/09/29008452/why-lava-therapeutics-stock-is-up-more-than-100-today,LVTX,0.712594,Somewhat-Bullish,0.330579
LAVA Therapeutics Skyrockets After Cancer Agreement With Seagen - Seagen  ( NASDAQ:SGEN ) ,20220926T123856,https://www.benzinga.com/general/biotech/22/09/29007424/lava-therapeutics-skyrockets-after-cancer-agreement-with-seagen,LVTX,0.629492,Bullish,0.472236
"Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors",20220926T120000,https://www.globenewswire.com/news-release/2022/09/26/2522463/0/en/Seagen-and-LAVA-Therapeutics-Announce-Exclusive-Worldwide-License-Agreement-to-Advance-LAVA-1223-a-Preclinical-Gamma-Delta-Bispecific-T-Cell-Engager-for-EGFR-Expressing-Solid-Tumor.html,LVTX,0.119532,Neutral,0.051644
LAVA Therapeutics N.V.  ( LVTX )  Upgraded to Buy: Here's What You Should Know,20220916T160006,https://www.zacks.com/stock/news/1981575/lava-therapeutics-nv-lvtx-upgraded-to-buy-heres-what-you-should-know,LVTX,0.358152,Somewhat-Bullish,0.344149
"LAVA Therapeutics N.V.  ( LVTX )  Reports Q2 Loss, Lags Revenue Estimates",20220913T212503,https://www.zacks.com/stock/news/1980122/lava-therapeutics-nv-lvtx-reports-q2-loss-lags-revenue-estimates,LVTX,0.396052,Neutral,0.00821
LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference,20220907T114100,https://www.globenewswire.com/news-release/2022/09/07/2511395/0/en/LAVA-Therapeutics-to-Present-at-the-H-C-Wainwright-24th-Annual-Global-Investment-Conference.html,LVTX,0.622414,Somewhat-Bearish,-0.153733
 ( LVTX )  - LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference,20220907T114100,https://www.benzinga.com/pressreleases/22/09/g28773583/lava-therapeutics-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference,LVTX,0.472338,Neutral,-0.045743
"Fstar Therapeutics, Inc.  ( FSTX )  Reports Q2 Loss, Lags Revenue Estimates",20220811T131507,https://www.zacks.com/stock/news/1967150/fstar-therapeutics-inc-fstx-reports-q2-loss-lags-revenue-estimates,LVTX,0.208764,Neutral,0.121379
"Cidara Therapeutics  ( CDTX )  Reports Q2 Loss, Lags Revenue Estimates",20220809T232512,https://www.zacks.com/stock/news/1966375/cidara-therapeutics-cdtx-reports-q2-loss-lags-revenue-estimates,LVTX,0.205225,Neutral,0.116627
LAVA Therapeutics N.V.  ( LVTX )  Expected to Beat Earnings Estimates: Can the Stock Move Higher?,20220808T140013,https://www.zacks.com/stock/news/1965354/lava-therapeutics-nv-lvtx-expected-to-beat-earnings-estimates-can-the-stock-move-higher,LVTX,0.256989,Neutral,0.127358
"Deciphera Pharmaceuticals, Inc.  ( DCPH )  Reports Q2 Loss, Tops Revenue Estimates",20220804T130513,https://www.zacks.com/stock/news/1963768/deciphera-pharmaceuticals-inc-dcph-reports-q2-loss-tops-revenue-estimates,LVTX,0.2035,Neutral,0.119008
LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Cancer Program,20220617T105936,https://www.benzinga.com/general/biotech/22/06/27758247/lava-therapeutics-highlights-encouraging-clinical-updates-on-lead-cancer-program,LVTX,0.640349,Neutral,0.002228
"LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients",20220616T200500,https://www.globenewswire.com/news-release/2022/06/16/2464341/0/en/LAVA-Therapeutics-Highlights-Encouraging-Clinical-Updates-on-Lead-Program-LAVA-051-in-Chronic-Lymphocytic-Leukemia-and-Multiple-Myeloma-Patients.html,LVTX,0.156461,Neutral,0.025135
LAVA Therapeutics Announces Two Appointments to its Board of Directors,20220615T110000,https://www.globenewswire.com/news-release/2022/06/15/2462948/0/en/LAVA-Therapeutics-Announces-Two-Appointments-to-its-Board-of-Directors.html,LVTX,0.151373,Somewhat-Bullish,0.275237
LAVA Therapeutics Announces Two Appointments to its Board of Directors,20220615T110000,https://www.benzinga.com/pressreleases/22/06/g27715260/lava-therapeutics-announces-two-appointments-to-its-board-of-directors,LVTX,0.109772,Bullish,0.435149
5 Value Stocks To Watch In The Healthcare Sector,20220606T152256,https://www.benzinga.com/news/22/06/27568435/5-value-stocks-to-watch-in-the-healthcare-sector,LVTX,0.213235,Neutral,0.00222
LAVA Therapeutics to Participate at the Jefferies Healthcare Conference,20220602T110000,https://www.benzinga.com/pressreleases/22/06/g27517609/lava-therapeutics-to-participate-at-the-jefferies-healthcare-conference,LVTX,0.458593,Neutral,0.005564
LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology  ( ASCO )  Annual Meeting,20220601T110000,https://www.globenewswire.com/news-release/2022/06/01/2454049/0/en/LAVA-Therapeutics-to-Present-Initial-Phase-1-2a-Clinical-Trial-Dose-Escalation-Data-of-LAVA-051-in-Chronic-Lymphocytic-Leukemia-and-Multiple-Myeloma-Patients-at-the-2022-American-S.html,LVTX,0.197482,Neutral,0.026314
Why LAVA Therapeutics  ( LVTX )  Might Surprise This Earnings Season,20220516T170600,https://www.zacks.com/stock/news/1924948/why-lava-therapeutics-lvtx-might-surprise-this-earnings-season,LVTX,0.891158,Neutral,0.106577
"The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More",20220512T124254,https://www.benzinga.com/general/biotech/22/05/27161064/the-daily-biotech-pulse-bristol-myers-bridgebio-ink-oncology-pact-fda-nod-for-lava-therapeutics-b,LVTX,0.080525,Neutral,0.001797
LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology  ( ASCO )  Annual Meeting,20220427T140500,https://www.benzinga.com/pressreleases/22/04/g26840247/lava-therapeutics-to-present-updated-lava-051-clinical-data-at-the-2022-american-society-of-clinic,LVTX,0.270673,Neutral,0.010705
LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology  ( ASCO )  Annual Meeting,20220427T140500,https://www.globenewswire.com/news-release/2022/04/27/2430444/0/en/LAVA-Therapeutics-to-Present-Updated-LAVA-051-Clinical-Data-at-the-2022-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html,LVTX,0.121496,Neutral,0.024531
LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022,20220310T113000,https://www.benzinga.com/pressreleases/22/03/g26076477/lava-therapeutics-to-present-at-the-oppenheimer-32nd-annual-healthcare-conference-2022,LVTX,0.413539,Neutral,0.036023
LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022,20220310T113000,https://www.globenewswire.com/news-release/2022/03/10/2400677/0/en/LAVA-Therapeutics-To-Present-at-the-Oppenheimer-32nd-Annual-Healthcare-Conference-2022.html,LVTX,0.348103,Neutral,0.011487
LAVA Therapeutics Shares Interim LAVA-051 Data From Early-Stage Cancer Trial,20220307T171904,https://www.benzinga.com/general/biotech/22/03/26021903/lava-therapeutics-shares-interim-lava-051-data-from-early-stage-cancer-trial,LVTX,0.420783,Neutral,0.002093
